2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 705

Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 706

Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Abstract Number: 707

Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
Abstract Number: 708

The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE
Abstract Number: 709

Differential Characteristics of Lupus Psychosis and Steroid Psychosis
Abstract Number: 710

An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Abstract Number: 711

Recurrence of Lupus Nephritis in Renal Transplant Recipients
Abstract Number: 712

Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Abstract Number: 713

Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage
Abstract Number: 714

A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 715

Septic Shock Among Patients with Systemic Lupus Erythematosus: Short and Long-Term Outcome and Cost. Analysis of the French Nationwide Database
Abstract Number: 716

Soluble CD163 Is a Biomarker Associated with Accelerated Carotid Atheroma in SLE Patients at Otherwise Low Risk for Cardiovascular Disease
Abstract Number: 717

The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study
Abstract Number: 718

Assessing Dyspnea in Patients with Systemic Lupus Erythematosus
Abstract Number: 719

Men and Sexual Function: An Overlooked Issue in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].